Tilray (NASDAQ:TLRY) Stock Price Down 1.5% – Time to Sell?

Tilray Inc (NASDAQ:TLRY)’s stock price fell 1.5% during trading on Monday . The company traded as low as $1.26 and last traded at $1.28. 34,431,125 shares changed hands during trading, an increase of 32% from the average session volume of 26,072,732 shares. The stock had previously closed at $1.30.

Analysts Set New Price Targets

Separately, Roth Mkm decreased their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a report on Friday, October 11th.

Tilray Trading Down 2.3 %

The company’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.69. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The stock has a market capitalization of $1.16 billion, a PE ratio of -4.74 and a beta of 2.09.

Tilray (NASDAQ:TLRY) last issued its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The company had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. During the same period in the previous year, the firm earned ($0.10) earnings per share. Tilray’s quarterly revenue was up 13.0% compared to the same quarter last year. As a group, analysts expect that Tilray Inc will post -0.14 earnings per share for the current year.

Insider Buying and Selling at Tilray

In other Tilray news, CFO Carl A. Merton purchased 26,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now directly owns 26,000 shares in the company, valued at approximately $35,360. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.87% of the company’s stock.

Hedge Funds Weigh In On Tilray

Large investors have recently made changes to their positions in the stock. Ferguson Wellman Capital Management Inc. purchased a new position in shares of Tilray in the 3rd quarter valued at about $26,000. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Tilray during the second quarter worth about $29,000. Jeppson Wealth Management LLC purchased a new stake in shares of Tilray during the second quarter worth about $33,000. Pallas Capital Advisors LLC purchased a new stake in shares of Tilray during the second quarter worth about $37,000. Finally, Vanguard Capital Wealth Advisors acquired a new stake in shares of Tilray in the second quarter worth approximately $34,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.